The global artificial intelligence (AI) in precision medicine market is undergoing unprecedented expansion as technology reshapes the future of personalized healthcare. Valued at USD 2.21 Billion in 2025, the market is projected to skyrocket to USD 46.45 Billion by 2035, growing at a remarkable CAGR of 35.60% from 2026 to 2035. Increasing adoption of precision medicine, rising healthcare digitization, and surging investments in AI-driven R&D are key factors propelling this growth.

Introduction: AI Becomes the Backbone of Personalized Healthcare

Precision medicine aims to deliver the right treatment to the right patient at the right time. Artificial intelligence has become a crucial enabler of this approach by accelerating diagnostics, optimizing drug discovery, and improving treatment decision-making through predictive analytics. AI tools now integrate genomics, imaging, patient records, and real-time data to provide unmatched accuracy in disease detection and personalized therapy design.

As governments, healthcare providers, and pharmaceutical companies increase spending on advanced computational technologies, AI-enhanced precision medicine continues to evolve rapidly, transforming global healthcare outcomes.

Detailed Market Analysis

1. Growing Demand for Precision Medicines

The global rise in chronic diseases, genetic disorders, and treatment-resistant conditions has increased the need for personalized therapeutic approaches. AI allows clinicians to analyze large datasets and tailor treatments with greater accuracy.

2. Advancements in AI Research and Development

High investment in AI-based tools—machine learning, deep learning, and neural networks—is accelerating the development of targeted therapies, molecular-level diagnostics, and predictive treatment models. Pharmaceutical companies are leveraging AI to drastically reduce drug discovery timelines.

3. Increasing Use of Genomic and Real-Time Patient Data

AI enhances the analysis of complex genomic profiles, enabling rapid detection of mutations and biomarkers. Integration of wearable devices and digital health platforms further strengthens data-driven precision care.

4. Strong Adoption Across Healthcare Organizations

Hospitals and diagnostic centers are deploying AI systems for improved clinical decision-making, early disease detection, and patient stratification. Demand for AI-enabled imaging solutions, predictive models, and risk assessment tools continues to rise.

5. Rapid Expansion of AI Infrastructure

Tech giants and healthcare leaders are investing in cloud computing, high-performance processors, and AI-enabled platforms—driving accessibility, scalability, and affordability of advanced precision medicine solutions.

Request a free report sample with a structured, detailed TOC overview.

Key Companies in the Market

Leading players driving innovation in AI-powered precision medicine include:

Novo Nordisk A/S

GE Healthcare

Intel Corporation

NVIDIA Corporation

Microsoft Corporation

Alphabet Inc.

IBM Corporation

Enlitic Inc.

AstraZeneca

Sanofi

These companies are advancing AI algorithms, computational platforms, and collaborative research initiatives to support next-generation personalized treatments.